The purpose of the present study is to obtain more information on the transit of orally ingested probiotics to the vagina.
Probiotics have emerged as novel supplements to support women's health, demonstrating benefits in maintain vaginal health and promoting recovery from dysbiosis. This includes various oral and vaginal probiotics shown to alleviate symptoms and enhance the reversal of vaginal dysbiosis. Oral delivered probiotic strains suggest their ability to migrate and colonize the vagina to support vaginal health but is not well understood. Therefore, this study will aim to provide additional information on their transit to the vagina.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
72
Includes 2 different probiotic strains differing from other intervention groups.
Includes 2 different probiotic strains differing from other intervention groups.
Includes 2 different probiotic strains differing from other intervention groups.
Evalulab
Montreal, Canada
RECRUITINGPresence or absence of probiotic stains in vaginal swabs after 28 days of oral intake
Time frame: 28 days of oral intake
Presence or absence of the probiotic stains in the vaginal swabs at days 0 & 14 of oral intake, and 1 week after the end of intervention (Day 35)
Time frame: From enrollment to day 35
Presence or absence of the probiotic strains in perineal skin swabs at days 0, 14, and 28 of oral intake.
Time frame: From enrollment to the 28th day.
Presence or absence of the probiotic strains in stool samples at days 0, 14 and 28 of oral intake.
Time frame: From enrollment to 28th day
Viability of the probiotic strains recovered from vaginal swabs at days 0, 14, and 28 of oral intake, and 1 week after the end of the intervention (Day 35)
Time frame: From enrollment to the 35th day.
Viability of the probiotic strains recovered from perineal skin swabs at day 0, 14, and 28 of oral intake.
Time frame: From enrollment to 28th day
Changes in vaginal pH from baseline to 1 week after the end of the intervention (Day 35)
Time frame: From baseline to day 35.
Changes in the abundance of endogenous and pathogenic bacterial and fungal species in the vagina at days 0, 14, 28 and 35.
Time frame: From enrollment to the 35th day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.